Boulet L P
Centre de Pneumologie, Hôpital Laval, Sainte-Foy, Québec.
Rev Mal Respir. 1992;9 Suppl 1:R11-3.
Salmeterol is a new long acting bronchodilator which is specific for beta-2 adrenergic receptors. Its bronchodilator effects can persist for at least 12 hours after inhalation. This drug can inhibit the bronchoconstrictor effects of methacholine up to 12 hours after inhalation and this effect is proportional to the administered dose. Salmeterol improves daily expiratory flow rates and blocks exercise-induced bronchoconstriction. A 50 micrograms dose, inhaled before an antigenic bronchoprovocation, can markedly reduce for up to 24 hours the immediate and late bronchospastic responses to antigen. Moreover, salmeterol inhibits the increase in bronchial responsiveness induced by antigenic exposure. This latter effect does not seem to be related to a persisting bronchodilatation. The responsible mechanisms for this inhibition of allergic response or if its effects are only due to a functional antagonism remain to be explored. A particularly relevant point would be to determine of salmeterol diminishes or blocks the inflammatory bronchial asthmatic reaction.
沙美特罗是一种新型长效支气管扩张剂,对β-2肾上腺素能受体具有特异性。吸入后其支气管扩张作用可持续至少12小时。该药物吸入后长达12小时可抑制乙酰甲胆碱的支气管收缩作用,且这种作用与给药剂量成正比。沙美特罗可改善每日呼气流量并阻止运动诱发的支气管收缩。在抗原性支气管激发试验前吸入50微克剂量,可显著减少对抗原的即时和迟发性支气管痉挛反应长达24小时。此外,沙美特罗可抑制抗原暴露引起的支气管反应性增加。后一种作用似乎与持续的支气管扩张无关。这种对过敏反应的抑制作用的相关机制,或者其作用是否仅归因于功能性拮抗作用,仍有待探索。一个特别相关的要点是确定沙美特罗是否能减轻或阻断炎症性支气管哮喘反应。